Deutsche Bank Rates Spyre Therapeutics (SYRE) buy
Deutsche Bank maintains its Buy rating for Spyre Therapeutics with a price target of $135, a 52.25% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Deutsche Bank rated Spyre Therapeutics, Inc. ($SYRE) "buy" with a $135 price target on June 23, 2026.
Since the rating, $SYRE is down 8.5% after 1 week, up 3.0% after 1 month and down 17.7% to date (from the $97.05 close on Jun 23, 2026).
SYRE
Spyre Therapeutics, Inc.
Key Points
- Deutsche Bank reiterated its Buy rating on Spyre Therapeutics, Inc. (SYRE) with a price target of $135 as of June 23, 2026.
- Deutsche Bank's $135 price target implies 52.25% upside from Spyre Therapeutics, Inc.'s ($SYRE) current $88.67 share price.
- Shares of Spyre Therapeutics traded at $100.32 on Tuesday, with a market cap around $8.71 billion and a forward P/E of -32.17.
- Recent insider activity at Spyre includes multiple transactions by executives, with Chief Medical Officer Sloan Sheldon selling shares on June 3, 2026.
Get $SYRE trade alerts by text
We text you when insiders, Congress or big funds trade $SYRE. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Spyre Therapeutics, Inc. alert may contain errors. Disclosures
Deutsche Bank has reiterated its Buy rating on Spyre Therapeutics, Inc. (SYRE) as of June 23, 2026, maintaining a price target of $135. Spyre Therapeutics is a biotechnology company focused on developing treatments for inflammatory bowel disease and other rheumatic diseases.
Deutsche Bank vs. the S&P 500
Hypothetical returns from Deutsche Bank's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Spyre Therapeutics
Several institutional investors have recently adjusted their holdings in Spyre Therapeutics. FMR LLC increased its stake by 142,205 shares, bringing its total to 11,781,024 shares valued at about $594.2 million, marking a 1.2% increase. BlackRock, Inc. slightly reduced its position by 880 shares, ending with 5,521,221 shares worth approximately $278.5 million. Perceptive Advisors LLC made a notable increase of 714,000 shares, growing its holdings by 23.3% to 3,783,225 shares valued at $190.8 million.
Spyre Therapeutics, Inc. Stock Down 1.8%
Shares of NasdaqGS:SYRE traded near $100.32 on Tuesday. Spyre Therapeutics has a market cap of approximately $8.71 billion and a forward P/E ratio of -32.17, indicating the company is not currently profitable. The stock's 52-week range is between $14.00 and $101.71, with a 50-day moving average of $72.73 and a 200-day moving average of $40.89. The company's beta is 3.063, suggesting higher volatility compared to the market.
$SYRE price target
Spyre Therapeutics, Inc. daily closes and this analyst's $135 target. Not advice.
Insider Buying and Selling at Spyre Therapeutics, Inc.
Recent insider transactions at Spyre Therapeutics include several by Chief Medical Officer Sloan Sheldon, who executed planned sales of 8,333 shares at $75.00 each on June 3, 2026. Additionally, Sheldon made an unplanned acquisition of 8,333 shares at $27.46 on the same day. Chief Financial Officer Scott Burrows purchased 7,500 shares at $14.50 on June 1, 2026, and executed planned sales of the same number of shares at $71.06.
Analysts Set New Price Targets
On June 23, 2026, Deutsche Bank maintained its Buy rating on Spyre Therapeutics with a price target of $135. BTIG also maintained its Buy rating with a target of $112 on June 16, 2026. The overall analyst consensus is a strong buy, with a mean target price of $99.13 based on 15 analyst opinions.
About Spyre Therapeutics
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts. It focuses on developing innovative therapies for inflammatory bowel disease and rheumatic diseases. The company’s pipeline includes several monoclonal antibodies targeting different pathways involved in these diseases. Dr. Cameron Turtle serves as the CEO, leading a team of 112 employees.
Bottom Line
Spyre Therapeutics remains a focus for investors, with Deutsche Bank's reiterated Buy rating and a price target of $135 highlighting potential growth. Institutional and insider activities reflect ongoing interest and investment in the company. As a clinical-stage biotech firm, Spyre's future performance will be closely watched, especially as it approaches its next earnings report on August 4, 2026.
Related Filing Alerts
Source: Deutsche Bank's rating change on $SYRE (Jun 23, 2026). Written by software, not financial advice. How we make alerts